

# Consolidated Financial Highlights for the Third Quarter of FY2016

(From April 1, 2016 to December 31, 2016)



NIHON KOHDEN CORPORATION

(Ticker Code: 6849)

**February 1, 2017** 



# 1) Consolidated Financial Results for the 3<sup>rd</sup> Quarter of FY2016

		FY2015 3Q	FY2016 3Q	YoY (%)	(Amounts of less than ¥1 million are rounded down)			
		9 months	9 months	` '				
	Net Sales	111,654	110,619	-0.9				
	Domestic Sales	81,094	83,011	2.4				
	Overseas Sales	30,560	27,607	-9.7 <sup>-</sup>	+3% on a local currency basis			
	Operating Income	7,247	5,302	-26.8	FY2015 3Q FY2016 3Q Gross Margin Ratio: 48.8% → 48.5% SG&A Ratio: 42.3% → 43.7%			
	Ordinary Income	7,588	6,046	-20.3 <sup>-</sup>	Fy2015 3Q Fy2016 3Q			
П	ncome Attributable to Owners of Parent	4,650	3,825	-17.8	¥140 mil losses → ¥250 mil gains			
	Average Exchange Rate	(2015/12)	(2016/12)					
	1 US Dollar	121.6 yen	107.4 yen					
	1 EURO	133.9 yen	118.6 yen					



# 2) Highlights of FY2016 3Q

### **Net Sales : -0.9%**

- Japan: Sales increased as the Company reorganized its sales operations to match each market: the acute care hospital market, the small and midsized hospital market, and the clinic market. Consumables and services also contributed to sales increase.
- International: Sales in all areas and all product categories decreased due to yen appreciation. Sales in the Americas and Asia increased on a local currency basis.

## Operating Income: -26.8%

 Operating income decreased due to sales decrease and due to increase in SG&A expenses such as R&D expenses and enhancement of human resources.

### Ordinary Income: -20.3%

 Foreign exchange gains were recorded compared to foreign exchange losses in the same period of FY2015.



# 3) Sales by Product Category

(Sales, millions of yen)

	FY2015 3Q 9 months	FY2016 3Q 9 months	YoY (%)
Physiological Measuring Equipment	26,450	26,006	-1.7
Patient Monitors	37,271	37,232	-0.1
Treatment Equipment	22,164	20,948	-5.5
Other Medical Equipment	25,768	26,431	2.6
Total Sales	111,654	110,619	-0.9
(Reference)			
Consumables and Services	48,683	50,956	4.7


# Sales Composition by Product Category

 $(FY2015 3Q \Rightarrow FY2016 3Q)$ **Physiological** Other Medical Measuring **Equipment Equipment** 23.0 **⇒** 23.9% **23.7** ⇒ **23.5**% Consumables and Services 43.6 ⇒46.1% Sales ¥110.6 billion **Treatment Medical devices Equipment** 56.4 **⇒**53.9% **Patient** 9.9 ⇒ <mark>18.9%</mark> **Monitors**  $33.4 \Rightarrow 33.7\%$ 



# 4) Domestic Sales

Sales by Market



#### Sales by Product Category

(Sales, millions of yen)

	FY2015 3Q 9 months	FY2016 3Q 9 months	YoY (%)
Physiological Measuring Equipment	20,002	20,335	1.7
Patient Monitors	23,437	24,448	4.3
Treatment Equipment	15,601	15,153	-2.9
Other Medical Equipment	22,052	23,074	4.6
Total Sales	81,094	83,011	2.4

**(Markets)** Sales in the private hospital and clinic market showed strong growth. Sales in the public hospital market increased. Sales in the university market decreased.

[Products] Physiological Measuring Equipment: Sales of polygraphs for cath labs increased favorably. Sales of EEGs, ECGs and diagnostic information system decreased.


**Patient Monitors:** Sales increased favorably, reflecting demand for differentiating and strengthening medical institution functions. Consumables such as sensors also contributed to sales increase.

**Treatment Equipment:** Sales of defibrillators and AEDs decreased. Sales of ventilators, pacemakers and ICDs increased. **Other Medical Equipment:** Sales of hematology instruments increased.



# 5) Overseas Sales

**Geographic Segments** 



## Percentage of Overseas Sales to Consolidated Sales

FY2015 3Q	FY2016 3Q
9 months	9 months
27.4%	25.0%

#### **Sales by Product Category**

(Sales, millions of yen)

	FY2015 3Q 9 months	FY2016 3Q 9 months	YoY (%)
Physiological Measuring Equipment	6,447		-12.0
Patient Monitors	13,834	12,784	-7.6
Treatment Equipment	6,562	5,794	-11.7
Other Medical Equipment	3,715	3,357	-9.6
Total Sales	30,560	27,607	-9.7

+3% on a local currency basis

**(Region)** Americas: Sales in the U.S. increased on a local currency basis. Sales in Latin America decreased mainly due to change in distribution channels.

**Europe:** Sales decreased, especially in Germany, although orders improved from the 3<sup>rd</sup> quarter.

**Asia:** Sales in Southeast Asia and India increased favorably. Sales in oil producing countries in the Middle East decreased due to negative effects of lower oil prices.

[Products] Physiological Measuring Equipment: Sales of EEGs and ECGs decreased in all areas.

Patient Monitors: Sales decreased in the Americas, Europe and Asia. Sales in other area increased favorably.

**Treatment Equipment:** Sales of defibrillators decreased in all areas. Sales of AEDs increased in Europe and Asia and decreased in the Americas.

Other Medical Equipment: Sales of hematology analyzers decreased in Asia.



# 6) Depreciation & R&D Costs

(Millions of yen)

	FY2015 3Q	FY2016 3Q	Change	Change FY2015		FY2016		
	9 months	9 months		Actual	Original Forecast announced May 11	Revised Forecast announced Nov 4		
Depreciation	2,503	2,461	-42	3,459	4,000	3,400		
R&D costs	4,058	4,474	415	5,910	7,300	6,500		

#### FY2016 capital investments plan:

- ➤ Molds for new products, measuring equipment and jigs, products for demonstration, production equipment, and renovation of Tomioka 2<sup>nd</sup> Plant and head quarters (Nishiochiai Office)
- Establish Advanced Technology Center in Tokorozawa

Completion and relocation: Oct 2016

Capital investments: 7.2 billion yen FY2015: 3.4 billion yen FY2016: 3.8 billion yen

Establish new facility in Asaka (Relocation of immunochemical products department)

Completion and relocation: Dec 2016

Capital investments:

1.1 billion yen 
FY2015: 0.2 billion yen 
FY2016: 0.9 billion yen



# 7) Forecast for FY2016

(¥billion, Amounts of less than ¥10 million are rounded down)

		EV2015	FY2016 Forecast				VoV
		FY2015 Actual	Original announced May 11	Revision announced Nov 4 (A)	Revision announced Feb 1 (B) *	Difference (B-A)	YoY (%)
	Net Sales	165.5	175.0	170.5	168.0	-2.5	1.5
	Domestic Sales	121.9	127.0	126.3	124.0	-2.3	1.6
	Overseas Sales	43.5	48.0	44.2	44.0	-0.2	1.1
	Operating Income	16.4	17.5	17.0	15.5	-1.5	-5.7
	Ordinary Income	16.1	17.5	16.0	16.0	_	-0.7
Income Attributable to Owners of Parent		10.5	11.5	10.7	10.3	-0.4	-2.1
	Percentage of Overseas Sales	26.3%	27.4%	25.9%	26.2%		
	Average Exchange Rate						
	1 US Dollar	120.1 yen	109 yen	104 yen	109 yen		
	1 EURO	132.4 yen	123 yen	116 yen	119 yen		

### +12% on a local currency basis

# Breakdown of overseas sales by region

	FY2015	FY20	YoY		
	Actual	Original announced May 11	Revision announced Nov 4	Revision announced Feb 1	(%)
Americas	19.4	21.3	19.9	20.4	4.9
Europe	8.0	8.7	7.7	7.4	-8.5
Asia	13.8	15.7	14.2	13.6	-2.0
Other	2.1	2.3	2.4	2.6	22.9

\*Notes: The assumed exchange rates are 112 yen to the dollar and 122 yen to the euro for the 4<sup>th</sup> quarter.



## 8) Reason for the Revision

#### Net Sales (down ¥2.5bil from previous forecast)

#### Domestic Sales (down ¥2.3bil)

- •The number of large orders from universities and public hospitals is expected to be less than FY2015. There were some postponements of and restraints on their spending from the 2<sup>nd</sup> half of FY2016.
- •Sales in the private hospital and clinic market will remain favorable.
- •Focus on sales activities of consumables and services.

#### Overseas Sales (down ¥0.2bil)

- •Sales in the Americas are expected in line with estimates.
- In Europe, sales recovery in Germany is expected to be weak. Sales in Asia will be negatively impacted by the political unrest in South Korea and the abolition of high-value rupee notes in India.
- In the other area, sales of a large order in Egypt will be recorded in the 4<sup>th</sup> quarter.
- •The assumed exchange rates were changed due to yen depreciation. (1 US Dollar: from ¥104 to ¥109, 1 EURO: from ¥116 to ¥119)

### Operating Income (down ¥1.5 bil)

- •Revised downward as sales are expected to be lower than the previous forecast.
- Improve profitability by promoting cost reductions and strengthening expense management.
- •Continue necessary investments such as enhancement of human resources, considering the business performance.

# Ordinary Income (same as previous forecast)

•After the 3<sup>rd</sup> quarter, foreign exchange gains are recorded.

# Income Attributable to Owners of Parent (down ¥0.4bil)

Extraordinary losses such as office transfer cost will be recorded in the 4<sup>th</sup> quarter.



# (Ref.) Consolidated Forecast for FY2016 by Product Category

(Amounts of less than ¥1 million are rounded down)

	FY2015	FY2015 FY2016 Foreca		ast	YoY
	Actual	Original announced May 11	Revision announced Nov 4	Revision announced Feb 1	(%)
Physiological Measuring Equipment	39,218	40,800	39,600	39,500	0.7
Patient Monitors	54,823	59,250	57,900	56,850	3.7
Treatment Equipment	30,611	32,600	30,700	29,900	-2.3
Other Medical Equipment	40,868	42,350	42,300	41,750	2.2
Total	165,522	175,000	170,500	168,000	1.5
(Reference)					
Consumables and Services	67,684	72,400	71,900	71,700	5.9



#### Disclaimer:

Contents described in this document are based on the Company's best judgments at the time it was prepared and do not constitute a guarantee or promise that the Company will achieve its numerical targets or implement the measures.